|
|
|
| Effects of Astragalus Polysaccharide Injection on Liver Function, Lipid and Glucose Metabolism, and Immune System in Patients Undergoing Radiotherapy and Chemotherapy after Lung Cancer Surgery |
| YAO Yan-chun; ZHANG Zhen |
| The Central Hospital of Anshan ,Anshan City, LiaoLin Province, 114001 |
|
|
|
Abstract 【Objective】To explore the effects of Astragalus polysaccharides injection on liver function, lipid and glucose metabolism, and immune function in patients undergoing radiotherapy and chemotherapy after lung cancer surgery. 【Methods】Eighty-seven patients with NSCLC were divided into the observation group (A group,n=45) and the control group (B group,n=42). Patients in the two groups were treated with the same radiotherapy and chemotherapy plan after surgery. In addition, patients in the A group were treated with Astragalus polysaccharides injection. Liver function indexes [alanine transaminase (ALT), aspartate aminotransferase (AST)], glucose and lipid metabolism indexes [fasting plasma glucose (FPG), postprandial 2h plasma glucose (2hPG), high density lipoprotein (HDL-C)] and immune indexes(CD4+,CD8+)] were compared between the two groups before and after treatment. 【Results】Before treatment, there were no significant differences in all indexes between the two groups(P>0.05). After treatment, ALT and AST in the two groups were increased (P<0.05). However, those changes in the A group were lower than those in the B group
(P<0.05). In the comparison of before and after treatment, there were no significant changes in levels of FPG, 2hPG and HDL-C in the A group (P>0.05). On the other hand, levels of FPG, 2hPG, and HDL-C in B group after treatment were higher than before treatment and the levels in the A group after treatment (all P<0.05). After treatment, there were no significant changes of CD8+ between the two groups (P>0.05). However, the CD4+ rate in the A group after treatment was higher than that before treatment and post-treatment in B group (all P<0.05). 【Conclusion】Astragalus polysaccharides injection can effectively reduce liver function damage, enhance immune function, relieve the elevation of blood glucose and blood lipids induced by chemotherapy and improve the tolerance of patients undergoing radiotherapy and chemotherapy after lung cancer surgery.
|
|
Received: 16 August 2016
|
|
|
|
|
|
[1] 王少言,初巍巍,霍阳,等.黄芪注射液对重症急性胰腺炎大鼠外周血清氧化相关物质的影响[J].解放军医药杂志,2014,26(12):5-7.
[2] 吴国明,范晔.晚期非小细胞肺癌靶向治疗研究进展及思考[J].西部医学,2012,24(1):1-4.
[3] Vassalou H,Stathopoulos E,Fiolitaki G,et al.Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy[J].Lung Cancer,2013,82(2):324-329.
[4] 王云启,梁慧,何欣,等.肺复康方对中晚期肺鳞癌的治疗效果观察[J].湖南师范大学学报(医学版),2014,11(2):30-32.
[5] Westeel V,Quoix E,Puyraveau M,et al.A randomised trial comparing preoperative to perioperative chemotherapy in early-stage non-small-cell lung cancer (IFCT 0002 trial)[J].Eur J Cancer,2013,49(12):2654-2664.
[6] 张颖,谢娅,李小平,等.化疗对妇科恶性肿瘤患者脂代谢的影响[J].中国医学创新,2014,11(7):9-11,12.
[7] 马国安.吉西他滨、培美曲塞、多西他赛联合顺铂治疗晚期肺腺癌的临床疗效研究[J].医学临床研究,2015,32(3):585-587.
[8] 姚兰,蒋成霞,唐元英,等.晚期非小细胞肺癌患者GP方案引起血糖升高的干预研究[J].实用糖尿病杂志,2015,11(2):53-55. |
|
|
|
2017, Vol. 34 
